Milk Thistle for Liver Cirrhosis

Finding: Across 13 RCTs (915 patients with alcoholic and/or hepatitis B or C liver disease), milk thistle showed no significant effect on all-cause mortality (RR 0.78, 95% CI 0.53 to 1.15). Liver-related mortality was significantly reduced when all trials were combined (RR 0.50, 95% CI 0.29 to 0.88) but NOT when restricted to high-quality trials (RR 0.57, 95% CI 0.28 to 1.19). No significant effect on complications or liver histology.

Finding: 4-year survival was 58 ± 9% in the silymarin group versus 39 ± 9% in placebo (P=0.036); 24 deaths in silymarin group versus 37 in placebo. Subgroup benefit seen in alcoholic cirrhosis (P=0.01) and Child A patients (P=0.03). This early positive trial was later judged of lower methodological quality and not confirmed in higher-quality studies.

Finding: In 200 alcoholics with biopsy- or laparoscopy-proven liver cirrhosis, silymarin did not produce a significant survival or clinical-course benefit over placebo, contradicting the earlier 1989 trial.

Finding: In 154 chronic hepatitis C patients who failed interferon, higher-than-customary silymarin doses did not reduce serum ALT more than placebo (only 2 per group reached the endpoint; mean ALT change P=0.75). No effect on HCV RNA.

Finding: High-dose silymarin significantly improved liver enzymes (ALT/AST P≤0.01), albumin (P=0.04), bilirubin (P=0.02), INR (P=0.03) and Child score (P=0.048) over 12 weeks; standard dose did not. These are surrogate biochemical endpoints, not mortality or hard clinical outcomes.